-- Lung cancer programs progressing with interim data updates expected in Q4 2025 -- -- Topline data from OnPrime Phase 3 ovarian cancer registrational trial expected in the second half of 2026 -- -- Cash, cash equivalents, short-term investments and restricted cash of $21.0 million as of September 30, 2025 -- WESTLAKE VILLAGE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the third quarter o ...

Declares Dividend of $0.15 per share for Q3 2025Represents Genco’s 25th Consecutive Quarterly Dividend NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Genco Shipping & Trading Limited (NYSE:GNK) (“Genco” or the “Company”), the largest U.S. headquartered drybulk shipowner focused on the global transportation of commodities, today reported its financial results for the three months and nine months ended September 30, 2025. Third Quarter 2025 and Year-to-Date Highlights Dividend Declared a $0.15 per share dividend ...

SCYNEXIS to receive one-time payments totalling $24.8 million from GSK as part of the resolution of the disagreement related to the restart of the Phase 3 MARIO study in invasive candidiasis. Scynexis agreed to GSK’s request to terminate the study.Following the positive SAD/MAD data results announced in September for SCY-247, its second-generation fungerp, the Company expects to initiate a Phase 1 study with the IV formulation and a Phase 2 study for the treatment of invasive candidiasis. The Company aims t ...

MONTREAL, Nov. 05, 2025 (GLOBE NEWSWIRE) -- OR Royalties Inc. (the “Company” or “OR Royalties”) (OR: TSX & NYSE) is pleased to announce that the Board of Directors has approved a fourth quarter 2025 dividend of US$0.055 per common share. The dividend will be paid on January 15, 2026 to shareholders of record as of the close of business on December 31, 2025. This dividend is an "eligible dividend" as defined in the Income Tax Act (Canada). For shareholders residing in Canada, the Canadian dollar equivalent w ...

Reaffirms 2025 adjusted earnings guidance in the range of $4.00 to $4.20 per share, excluding merger-related costs, same as prior GAAP guidanceCompleted planned equity and debt financing activities for 2025Filed settlement agreement for new customer rates at Nebraska natural gas utilityCompleting construction of Ready Wyoming 260-mile transmission expansion project to be in service by year-endCommenced construction of Lange II 99 MW generation facility in South Dakota to be in service during second half of ...

HOUSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- APA Corporation (Nasdaq: APA) today announced third-quarter 2025 results. Results can be found on the company’s website by visiting www.apacorp.com or investor.apacorp.com. APA will host a conference call on Nov. 6 at 10 a.m. Central time via the webcast link available on the company website to discuss the results. Following the conference call, a replay will be available for one year on the “Investors” page of the company’s website. About APA APA Corporation owns ...

Dallas, Texas, Nov. 05, 2025 (GLOBE NEWSWIRE) -- CompX International Inc. (NYSE American: CIX) announced today net sales of $40.0 million for the third quarter of 2025 compared to $33.6 million in the same period of 2024. Operating income was $4.8 million in the third quarter of 2025 compared to $3.3 million in the same period of 2024. Net income was $4.2 million, or $.34 per basic and diluted common share, for the third quarter of 2025 compared to $3.5 million, or $.28 per basic and diluted common share, i ...

HUNTINGTON BEACH, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- BJ’s Restaurants, Inc. (NASDAQ: BJRI) today announced that Todd Wilson has been appointed Chief Financial Officer (“CFO”), effective December 15, 2025. Mr. Wilson brings nearly two decades of exceptional financial leadership to BJ’s. Most recently and since November 2022, Mr. Wilson has served as the CFO of Red Robin Gourmet Burgers, Inc., a publicly traded full-service restaurant chain, where he played an integral role in improving restaurant-lev ...

– Corporate Credit Rating Upgraded to Investment-Grade – Reduced Net Debt by $2 Billion Since Q3’24 and Increased Liquidity to $1.1 Billion – Executed $1.8 Billion Refinancing of Revolving Credit Facility, Lowering Cost of Capital and Extending Weighted Average Debt Maturity – Repurchased 12.1 Million Shares Year-to-Date at a Weighted Average Price of $7.59, Totaling $92 Million – Raises Full-Year AFFO per Share Guidance to New Range of $0.95 to $0.97 from $0.92 to $0.96 NEW YORK, Nov. 05, 2025 (GLOBE NEWS ...

Ongoing Phase 1 trial of CTIM-76 (CLDN6 x CD3) demonstrates encouraging antitumor activity and safety Ongoing Phase 1 trial of CT-95 (MSLN x CD3) is approaching target dose levels Cash and cash equivalents of $76.9 million as of September 30, 2025 PHILADELPHIA, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today provided a clinical update and ...